MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 530900 | Name: Mitozolomide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mitozolomide is an Antineoplastic Agent.

Chemical Structure

Mitozolomide
Mitozolomide
CAS#85622-95-3

Theoretical Analysis

MedKoo Cat#: 530900

Name: Mitozolomide

CAS#: 85622-95-3

Chemical Formula: C7H7ClN6O2

Exact Mass: 242.0319

Molecular Weight: 242.62

Elemental Analysis: C, 34.65; H, 2.91; Cl, 14.61; N, 34.64; O, 13.19

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Mitozolomide
IUPAC/Chemical Name
Imidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide, 3-(2-chloroethyl)-3,4-dihydro-4-oxo-
InChi Key
QXYYYPFGTSJXNS-UHFFFAOYSA-N
InChi Code
InChI=1S/C7H7ClN6O2/c8-1-2-14-7(16)13-3-10-4(5(9)15)6(13)11-12-14/h3H,1-2H2,(H2,9,15)
SMILES Code
O=C(C1=C(N2C=N1)N=NN(CCCl)C2=O)N
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 242.62 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Fang Y, Wu J, Li T, Luo Y, Qiu Q, Quan X, Gao L, Liu W. Biological effects of novel "combi-targeting" molecule and its effect on DNA repair pathway in hormone-refractory prostate cancer. Am J Cancer Res. 2015 Jul 15;5(8):2387-95. eCollection 2015. PubMed PMID: 26396914; PubMed Central PMCID: PMC4568774. 2: Maggio B, Raimondi MV, Raffa D, Plescia F, Cascioferro S, Cancemi G, Tolomeo M, Grimaudo S, Daidone G. Synthesis and antiproliferative activity of 3-(2-chloroethyl)-5-methyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f ][1,2,3,5]tetrazepin-4-(3H)-one. Eur J Med Chem. 2015;96:98-104. doi: 10.1016/j.ejmech.2015.04.004. Epub 2015 Apr 6. PubMed PMID: 25874335. 3: Fang Y, Qiu Q, Domarkas J, Larroque-Lombard AL, Rao S, Rachid Z, Gibbs BF, Gao X, Jean-Claude BJ. "Combi-targeting" mitozolomide: conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer. Prostate. 2012 Sep 1;72(12):1273-85. doi: 10.1002/pros.22475. Epub 2012 Jan 30. PubMed PMID: 22290742. 4: Zhang J, Stevens MF, Laughton CA, Madhusudan S, Bradshaw TD. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. Oncology. 2010;78(2):103-14. doi: 10.1159/000306139. Epub 2010 Mar 31. PubMed PMID: 20357518. 5: Diana P, Barraja P, Lauria A, Montalbano A, Almerico AM, Dattolo G, Cirrincione G. Pyrrolo[2,1-d][1,2,3,5]tetrazine-4(3H)-ones, a new class of azolotetrazines with potent antitumor activity. Bioorg Med Chem. 2003 May 29;11(11):2371-80. PubMed PMID: 12735982. 6: Arrowsmith J, Jennings SA, Clark AS, Stevens MF. Antitumor imidazotetrazines. 41. Conjugation of the antitumor agents mitozolomide and temozolomide to peptides and lexitropsins bearing DNA major and minor groove-binding structural motifs. J Med Chem. 2002 Dec 5;45(25):5458-70. PubMed PMID: 12459014. 7: Mariani L, Piccirilli A, Citti L, Colombo MG, Poliseno L, Rainaldi G. The sensitivity of MCF10A breast epithelial cells to alkylating drugs is enhanced by the inhibition of O6-methylguanine-DNA methyltransferase transcription with a synthetic double strand DNA oligonucleotide. Breast Cancer Res Treat. 2002 Jun;73(3):207-13. PubMed PMID: 12160326. 8: Wang Y, Lambert P, Zhao L, Wang D. Synthesis and antibacterial activity of dual-action agents of a beta-lactam antibiotic with cytotoxic agent mitozolomide or temozolomide. Eur J Med Chem. 2002 Apr;37(4):323-32. PubMed PMID: 11960667. 9: Mariani L, Citti L, Nevischi S, Eckstein F, Rainaldi G. Ribozyme and free alkylated base: a dual approach for sensitizing Mex+ cells to the alkylating antineoplastic drug. Cancer Gene Ther. 2000 Jun;7(6):905-9. PubMed PMID: 10880022. 10: van Rijn J, Heimans JJ, van den Berg J, van der Valk P, Slotman BJ. Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):779-84. PubMed PMID: 10837964. 11: Fairbairn LJ, Chinnasamy N, Lashford LS, Chinnasamy D, Rafferty JA. Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide. Cancer Gene Ther. 2000 Feb;7(2):233-9. PubMed PMID: 10770631. 12: Clemons M, Watson A, Howell A, Chang J, Heyworth C, Lord B, Testa N, Dexter TM, Margison G. Macrophage inflammatory protein 1alpha attenuates the toxic effects of temozolomide in human bone marrow granulocyte-macrophage colony-forming cells. Clin Cancer Res. 2000 Mar;6(3):966-70. PubMed PMID: 10741722. 13: Arrowsmith J, Missailidis S, Stevens MF. Antitumour imidazotetrazines. Part 37. Conjugation of the DNA major-groove alkylating imidazotetrazine mitozolomide to peptide motifs recognizing the minor groove. Anticancer Drug Des. 1999 Jun;14(3):205-17. PubMed PMID: 10500496. 14: Citti L, Eckstein F, Capecchi B, Mariani L, Nevischi S, Poggi A, Rainaldi G. Transient transfection of a synthetic hammerhead ribozyme targeted against human MGMT gene to cells in culture potentiates the genotoxicity of the alkylation damage induced by mitozolomide. Antisense Nucleic Acid Drug Dev. 1999 Apr;9(2):125-33. PubMed PMID: 10355819. 15: Longhurst SJ, Rafferty JA, Arrand JR, Cortez N, Giraud C, Berns KI, Fairbairn LJ. Recombinant adeno-associated virus-mediated expression of O6-alkylguanine-DNA-alkyltransferase protects human epithelial and hematopoietic cells against chloroethylating agent toxicity. Hum Gene Ther. 1999 Jan 20;10(2):301-10. PubMed PMID: 10022554. 16: Jean-Claude BJ, Mustafa A, Watson AJ, Damian Z, Vasilescu D, Chan TH, Leyland-Jones B. Tetrazepinones are equally cytotoxic to Mer+ and Mer- human tumor cell lines. J Pharmacol Exp Ther. 1999 Feb;288(2):484-9. PubMed PMID: 9918549. 17: Citti L, Mariani L, Capecchi B, Piras A, Leuzzi R, Rainaldi G. The sensitization of cells treated with O6-methylguanine to alkylation damage is affected by the number of O6-methylguanine-DNA methyltransferase molecules escaped from inactivation. Mutat Res. 1998 Dec 14;409(3):173-9. PubMed PMID: 9875292. 18: Hickson I, Fairbairn LJ, Chinnasamy N, Lashford LS, Thatcher N, Margison GP, Dexter TM, Rafferty JA. Chemoprotective gene transfer I: transduction of human haemopoietic progenitors with O6-benzylguanine-resistant O6-alkylguanine-DNA alkyltransferase attenuates the toxic effects of O6-alkylating agents in vitro. Gene Ther. 1998 Jun;5(6):835-41. PubMed PMID: 9747464. 19: Jean-Claude BJ, Mustafa A, Damian Z, De Marte J, Vasilescu DE, Yen R, Chan TH, Leyland-Jones B. Comparative studies between the effects of mitozolomide and two novel tetrazepinones PYRCL and QUINCL on NIH:OVCAR-3 cells. Cancer Chemother Pharmacol. 1998;42(1):59-67. PubMed PMID: 9619759. 20: Hickson I, Fairbairn LJ, Chinnasamy N, Dexter TM, Margison GP, Rafferty JA. Protection of mammalian cells against chloroethylating agent toxicity by an O6-benzylguanine-resistant mutant of human O6-alkylguanine-DNA alkyltransferase. Gene Ther. 1996 Oct;3(10):868-77. PubMed PMID: 8908500.